Corporate ActionJul 31, 2026, 05:32 PM
BioVie to Offer Up to 56.4M Shares & Warrants in Best Efforts Offering
AI Summary
BioVie Inc. is conducting a "best efforts" public offering of up to 56,390,977 shares of Class A Common Stock and an equal number of Pre-funded Warrants. The offering, with an assumed price of $1.33 per share, aims to raise approximately $70.0 million in net proceeds for working capital, R&D, and potential acquisitions. The company also disclosed ongoing securities class action litigation and past clinical trial protocol violations that led to patient exclusions, impacting a Phase 3 Alzheimer's trial.
Key Highlights
- Offering up to 56,390,977 Class A Common Stock shares.
- Offering up to 56,390,977 Pre-funded Warrants.
- Assumed public offering price of $1.33 per share.
- Estimated net proceeds of $70.0 million if fully subscribed.
- Proceeds for working capital, R&D, and acquisitions.
- Offering is on a "best efforts" basis with no minimum.
- Company subject to ongoing securities class action litigation.
- Past Phase 3 trial had protocol violations, leading to patient exclusions.
Price Impact
More from BIVI